Condition: Endometrial Cancer · Near Infrared Fluorescence Imaging · CYTALUX (Pafolacianine) Injection · Sponsor: Abramson Cancer Center at Penn Medicine
The research study is being done to assess the safety and ability of an investigational drug called CYTALUX (pafolacianine) and a special camera system for the detection of cancer in patients undergoing surgical resection for endometrial cancer.
This description comes directly from the study's public registry record.
Brianna Aguilar · 215-615-6770 · brianna.aguilar@pennmedicine.upenn.edu
Joseph Agyemang · 215-490-4121 · joseph.agyemang@pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| Abramson Cancer Center at Penn Medicine | Philadelphia, Pennsylvania, United States | Recruiting |
| University of Pennsylvania Gynecologic Oncology Department | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07278986